Clinical trials: Breast Cancer, Breast Neoplasms
Metastatic Breast Cancer
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic signature or BRCA 1 or 2 somatic mutation…
- Trial name
- RUBY (NCT02505048)
- Testing
- rucaparib
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- UNICANCER
HR+HER2- Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after…
- Trial name
- NCT06343948
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer
Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening
The overall objective is to assess the acceptability and feasibility of offering personalized breast cancer (BC) screening. The specific objectives are: 1) To design an information system; 2) To evaluate the barriers and…
- Trial name
- DECIDO (NCT03791008)
- Testing
- Risk based screening
- Where
- Spain
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- Institut de Recerca Biomèdica de Lleida
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Metastatic Breast Cancer
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01421017
- Testing
- Radiation, Imiquimod, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Anxiety Disorder, Breast Cancer
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
- Trial name
- NCT00022074
- Testing
- gabapentin, quality-of-life assessment
- Where
- 18 sites in United States
- Sponsor
- Gary Morrow
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Breast Cancer, Circulating Tumor Cell
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients…
- Trial name
- CTCNeoBC-E (NCT05360290)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 484 people
- Sponsor
- RenJi Hospital
Breast Cancer
A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment
This is a three-month open-label, multicenter, interventional, single arm study located in France, designed to assess feasibility and reliability of the e-Health ZEMY software medical device under investigation for use by…
- Trial name
- ZEMY (NCT03558490)
- Testing
- ZEMY software, Investigator's choice of anti-cancer treatment (except immunotherapy)
- Where
- 5 sites in France
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer Lymphedema
Efficacy of Aquatic Physiotherapy in the Treatment of Upper Limb Lymphedema in Women With Breast Cancer.
This study aims to evaluate the effectiveness of Aquatic Therapeutic Exercise by providing a set of exercises in the reduction and / or control the volume of secondary lymphedema treatment of breast cancer in patients who are in…
- Trial name
- NCT05119049
- Testing
- Exercise guideline
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Isabel Lopez Zamora
Breast Cancer
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to evaluate the safety and tolerance of entinostat administered orally as a single agent in a weekly dosing schedule.
- Trial name
- NCT02833155
- Testing
- Entinostat, Exemestane
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Invasive Breast Cancer
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast
Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.
- Trial name
- NCT05703815
- Volunteers
- 40 people
- Sponsor
- Sohag University
Breast Cancer Awareness Training
Simple Simulation Based Breast Cancer Awareness Training
It was planned to determine the effect of simple simulation-based breast cancer awareness training on women's breast cancer knowledge and fear levels.
- Trial name
- NCT06528808
- Testing
- Simple reality simulator application
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Invasive Breast Cancer, Cavitation
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Blood perfusion insufficiency and hypoxia are the main causes of drug resistance to chemotherapy in breast cancer. Increasing blood perfusion can improve drug delivery.
- Conditions
- Invasive Breast Cancer, Cavitation, Perfusion
- Trial name
- NCT06158217
- Testing
- ultrasound combined with microbubbles
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Breast Neoplasms
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
This is a pilot phase 1b study to investigate the safety and side effects of combining the ROR1-targeting monoclonal antibody, cirmtuzumab, with paclitaxel for patients with HER2 negative, metastatic breast cancer.
- Trial name
- NCT02776917
- Testing
- Cirmtuzumab + Paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Parker, MD
Breast Cancer, Chronic Pain
Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery
Pre-existing pain and severe postoperative pain are predictors of persistent pain after surgery, but a complete understanding on the development of persistent pain is still lacking.
- Conditions
- Breast Cancer, Chronic Pain, Acute Pain, Depression, Anxiety
- Trial name
- B-CAPP (NCT03408717)
- Testing
- Questionnaires, Mechanical Temporal Summation assessment, Pain threshold assessment
- Where
- 2 sites in United States, Singapore
- Volunteers
- 220 people
- Sponsor
- KK Women's and Children's Hospital
Metastatic Breast Cancer in the Liver
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
The purpose of this study is to further use DCE-MRI and ivim-dwi to predict the chemotherapy sensitivity of liver metastasis of breast cancer at an early stage, and to predict the treatment response of tumor at an early stage by…
- Trial name
- DreaminLMBC (NCT05550090)
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Breast Cancer
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
The purpose of this study is to evaluate whether trastuzumab and letrozole are effective and safe in the preoperative treatment for postmenopausal patients with hormone receptor-positive and HER2-positive breast cancer.
- Trial name
- HERAKLES (NCT02214004)
- Testing
- Trastuzumab, Letrozole
- Where
- 14 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Gangnam Severance Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.